Collapsible content

1)   What does a Qualifying Transaction between HEMPALTA and TBV mean?

Trail Blazing Ventures Ltd. (TSXV: BLAZ.P) ("TBV") is a capital pool company (“CPC”), listed on the TSX Venture Exchange. TBV entered into a definitive amalgamation agreement (the "Amalgamation Agreement") with Hempalta Inc. ("HEMPALTA") on November 15, 2023, pursuant to which, HEMPALTA will amalgamate with TBV, and the shareholders of HEMPALTA will exchange their common shares for shares in the combined entity, Hempalta Corp. (the "Resulting Issuer") on a one for one basis (the "Transaction"). The Resulting Issuer will carry on the business of HEMPALTA and is expected to trade under the symbol HEMP on the TSXV following closing of the Transaction. 
Further details regarding the Transaction can be found in the information circular of TBV ("Circular"), which can be located on TBV’s SEDAR+ profile at

2)   When is the Annual General and Special Meeting (“AGSM”) to approve the qualifying transaction?

The AGSM is on March 15th at 10:00 AM MT at Suite 800, 333 7th Avenue S. W, Calgary, AB T2P 2Z1.

3)   Who is able to vote at the AGSM?

Shareholders of record of TBV as of the close of business on February 9, 2024 are invited to vote at the AGSM. Please refer to the proxy instructions received by mail on how to vote. 

4)   When do you expect the Transaction to close?

The closing of the Transaction is anticipated to take place on or about March 19, 2024, subject to the approval of the TBV shareholders of the Transaction.

5)   As a TBV shareholder, what happens to my TBV shares? As a HEMPALTA shareholder, what happens to my HEMPALTA shares?

As a TBV shareholder, following the completion of the Transaction, shareholders who hold their TBV shares through a broker will automatically be adjusted for the consolidation and new name of the Resulting Issuer. No further action is required by such shareholders. 
As a HEMPALTA shareholder, following the closing of the Transaction, each HEMPALTA Share shall be cancelled and the holder of such HEMPALTA Share will receive one (1) fully paid and non-assessable Resulting Issuer common share the ("RI Shares"). DRS statements representing the RI Shares will be mailed to registered shareholders following the closing of the Transaction by the Resulting Issuer's transfer agent, Odyssey Trust Company.

6)   What is the date DRS statements will be sent out to shareholders?

Registered HEMPALTA shareholders will be mailed their DRS statements from the transfer agent in connection with the closing of the Transaction; delivery times may vary. If your shares are held by a broker or other intermediary, the RI Shares will be sent to such intermediary. 

7)   How will I receive my DRS statement? 

DRS statements will be sent via regular mail or email to all shareholders registered address by the transfer agent. 

8)   What is the date Resulting Issuer's shares will be listed on the TSX Venture Exchange?

TBV anticipates the Resulting Issuer's shares will be listed and posted for trading for the market open, on or about March 22, 2024.

9)   What will the Resulting Issuer's trading symbol be?

The Resulting Issuer's expected trading symbol is "HEMP".

10)   What is the current value of the company?

The Company's market cap value will depend upon the trading price of common shares and will be found here once the shares commence trading:

11)   Where can I find your latest annual filings including the financial statements and MD&A for the year ended September 30, 2023?

TBV’s audited financial statements and MD&A for the year ended September 30, 2023, are available at HEMPALTA's audited financial statements can be located in the Circular, found on TBV’s SEDAR+ profile at

12)   I would like to change my email address for future correspondence. Who should I contact?

Please direct inquiries on this subject to
Statements in this FAQ regarding the TBV or Hempalta's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties, such as terms and completion of the proposed Transaction, and the date on which the RI Shares are expected to begin trading. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements. The forward-looking statements and circumstances discussed in this FAQ, including the completion of the Transaction may not occur or could differ materially as a result of known and unknown risk factors and uncertainties affecting TBV or Hempalta. No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made and, except as required by applicable securities laws, neither TBV or Hempalta undertakes any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.